Johnson & Johnson has filed an application seeking emergency use authorisation for its Covid-19 vaccine with the Food and Drug Administration, bringing the company one step closer to getting the first single-shot vaccine distributed in the US.
The world’s largest healthcare group said it expected to supply 100m doses to the US government in the first half of the year, boosting supplies and speeding up the vaccination rollout.
Last week, J&J published interim data that showed its vaccine had a 66 per cent efficacy rate for preventing moderate and severe disease, lower than the first shots approved from BioNTech/Pfizer and Moderna, but above the minimum bar of 50 per cent set by the US FDA.
您已阅读21%（696字），剩余79%（2683字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。